Questcor Launches New Corporate Website

v UNION CITY, Calif., July 9, 2009 (GLOBE NEWSWIRE) -- Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR) announced it has launched a new corporate website with an easier to navigate format and content that provides critical information for families, healthcare providers, employees, investors, and other stakeholders. The new website can be accessed at www.questcor.com. This website is linked to the recently launched website, www.acthar.com.

"Our new site provides doctors and patients with more direct ways to communicate with our customer service team and will improve our ability to assist in the delivery of effective treatment to patients," said Don M. Bailey, President and Chief Executive Officer of Questcor. "One of our key corporate goals is to ensure that each and every patient who needs our primary drug, H.P. Acthar(r) Gel, is provided access regardless of income level or insurance coverage. The new website will help us to continue to achieve that goal. In addition, the new website permits patients, physicians and shareholders to efficiently access the information they need."

About Questcor

Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets H.P. Acthar(r) Gel (repository corticotropin injection). H.P. Acthar Gel ("Acthar") is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis ("MS") and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythamatosus. In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The Company also markets Doral(r) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.

CONTACT: Questcor Pharmaceuticals, Inc.
Don Bailey
510-400-0776
dbailey@Questcor.com

EVC Group, Inc.
Investors
Doug Sherk
415-896-6820
Media
Christopher Gale
646-201-5431

Posted: July 2009

View comments

Hide
(web3)